A key opinion leader explores the integration of bispecifics into MM therapy regimens.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
When using bispecific antibodies in multiple myeloma (MM), proper sequencing with chimeric antigen receptor (CAR) T-cell therapy is important since they can target similar antigens. CAR T-cell therapy may be favored earlier given the one-and-done appeal and quality of life benefits shown in studies like CARTITUDE-4 and KarMMa. Bispecifics are now better managed with less concern about cytokine release syndrome, even allowing outpatient administration at some centers, potentially expanding community hospital access beyond academic sites.
While bispecifics don’t match CAR T-cell therapy response rates, their wider eligibility makes them an exciting option. They will also likely expand into solid tumors. However, infections remain a key long-term toxicity that requires prevention/proactive management with IgG replacement and antibiotics. Understanding optimal dosing and schedules for antibodies like talquetamab will also minimize cumulative toxicities like rash and weight loss that can impact quality of life. But with proper mitigation strategies, bispecifics have a promising future in myeloma.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More